StockTipsArenaBeta

BUY Aurobindo Pharma — Amit Seth

BUYAurobindo Pharma

byAmit SethHorizon: NA (inferred Intraday)24 Sept 2026, 11:31 am ISTvia CNBC Awaaz.

Entry₹1,732.4Inferred
Target₹1,775
Total upside +2.46% (call closed)
Stop loss₹1,712-1.18% risk
At expiry₹1,714.724 Sept 2026, 3:05 pm
Expired-1.02%
Follow Amit Seth for new calls(6% target hit, 71 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 24 Sept 2026
5 supporting1 neutral0 opposing
Supports the BUY call (5)

Aurobindo Pharma stock in focus after subsidiary Unit-IV receives VAI status from US FDA

NewsGoogle News·23 Sept · today

(opens in new tab)

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

NewsGoogle News·22 Sept · yesterday

(opens in new tab)

1 advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·21 Sept · 3d ago

Aurobindo Pharma stock edges higher as US tariff risks and FDA approvals shape outlook

NewsGoogle News·19 Sept · 4d ago

(opens in new tab)

Aurobindo Pharma Share Price rises: stock analysis note

NewsGoogle News·17 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Aurobindo Pharma AGM results: ₹4 dividend confirmed, K. Nithyananda Reddy reappointed amid dissent

NewsGoogle News·20 Sept · 4d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.